Gene fusions during the early evolution of mesothelioma correlate with impaired DNA repair and Hippo pathways
- PMID: 37421230
- DOI: 10.1002/gcc.23189
Gene fusions during the early evolution of mesothelioma correlate with impaired DNA repair and Hippo pathways
Abstract
Malignant pleural mesothelioma (MPM), a rare cancer a long latency period (up to 40 years) between asbestos exposure and disease presentation. The mechanisms coupling asbestos to recurrent somatic alterations are poorly defined. Gene fusions arising through genomic instability may create novel drivers during early MPM evolution. We explored the gene fusions that occurred early in the evolutionary history of the tumor. We conducted multiregional whole exome sequencing (WES) of 106 samples from 20 patients undergoing pleurectomy decortication and identified 24 clonal nonrecurrent gene fusions, three of which were novel (FMO9P-OR2W5, GBA3, and SP9). The number of early gene fusion events detected varied from zero to eight per tumor, and presence of gene fusions was associated with clonal losses involving the Hippo pathway genes and homologous recombination DNA repair genes. Fusions involved known tumor suppressors BAP1, MTAP, and LRP1B, and a clonal oncogenic fusion involving CACNA1D-ERC2, PARD3B-NT5DC2, and STAB2-NT5DC2 fusions were also identified as clonal fusions. Gene fusions events occur early during MPM evolution. Individual fusions are rare as no recurrent truncal fusions event were found. This suggests the importance of early disruption of these pathways in generating genomic rearrangements resulting in potentially oncogenic gene fusions.
Keywords: evolution; gene fusion; genomics; mesothelioma; transcriptomics.
© 2023 The Authors. Genes, Chromosomes and Cancer published by Wiley Periodicals LLC.
References
REFERENCES
-
- Zhai Z, Ruan J, Zheng Y, et al. Assessment of global trends in the diagnosis of mesothelioma from 1990 to 2017. JAMA Netw Open. 2021;4:e2120360.
-
- Abdel-Rahman O. Global trends in mortality from malignant mesothelioma: analysis of WHO mortality database (1994-2013). Clin Respir J. 2018;12:2090-2100.
-
- Liu B, van Gerwen M, Bonassi S, Taioli E, International Association for the Study of Lung Cancer Mesothelioma Task Force. Epidemiology of environmental exposure and malignant mesothelioma. J Thorac Oncol. 2017;12:1031-1045.
-
- Mavrakis KJ, McDonald ER 3rd, Schlabach MR, et al. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5. Science. 2016;351:1208-1213.
-
- Marjon K, Cameron MJ, Quang P, et al. MTAP deletions in cancer create vulnerability to targeting of the MAT2A/PRMT5/RIOK1 axis. Cell Rep. 2016;15:574-587.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
